Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nabeel Farooqui

Allergy & Immunology Fishers, IN Medical Doctor

NPI 1174732804 CMS profile 396643

11501 Cumberland Rd Ste 500, Fishers, IN 46037

Open in the dashboard

General payments

$1,210,952

1,822 records reported · program years 2019–2025

Research payments

$12,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$97,878 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Nabeel Farooqui of Fishers, IN is reported in the CMS Open Payments database as having received $1,210,952 across 1,822 general payments and $12,500 in research payments paid to them. Separately, studies naming them as principal investigator received $97,878 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $213,667 336
2024 General $224,467 335
2023 General $216,911 291
2022 General $173,544 250
2021 General $150,961 208
2020 General $72,604 156
2019 General $158,799 246
2019 Research $12,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nabeel Farooqui
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Nabeel Farooqui were reported at $213,667. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Nabeel Farooqui Allergy & Immunology median Middle half National median
2019 $158,799 $594 $163–$1,512 $163
2020 $72,604 $426 $106–$1,233 $114
2021 $150,961 $638 $157–$1,708 $132
2022 $173,544 $790 $205–$1,961 $149
2023 $216,911 $852 $220–$2,147 $160
2024 $224,467 $865 $203–$2,267 $164
2025 $213,667 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $554,719 547 payments
  2. AstraZeneca Pharmaceuticals LP $272,740 361 payments
  3. Teva Pharmaceuticals USA, Inc. $89,141 101 payments
  4. Regeneron Healthcare Solutions, Inc. $69,576 144 payments
  5. Genzyme Corporation $54,559 80 payments
  6. OptiNose US, Inc. $50,587 84 payments
  7. Genentech USA, Inc. $22,430 47 payments
  8. Novartis Pharmaceuticals Corporation $22,421 61 payments
  9. ARS Pharmaceuticals Operations, Inc. $16,098 20 payments
  10. Sanofi US Services Inc. $12,134 13 payments
  11. Other $46,546 364 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $917,769 370 payments
  2. Consulting Fee $145,438 59 payments
  3. Travel and Lodging $101,066 297 payments
  4. Food and Beverage $37,929 1,086 payments
  5. Honoraria $8,553 4 payments
  6. Education $181 4 payments
  7. Gift $17 2 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $469,919 406 payments
  2. AIRSUPRA $81,808 84 payments
  3. FASENRA Respiratory $72,216 80 payments
  4. NUCALA Respiratory $64,178 75 payments
  5. TEZSPIRE $60,366 83 payments
  6. DUPIXENT Inflammation And Immunology $59,314 123 payments
  7. DUPIXENT Immunology $55,554 103 payments
  8. Xhance $50,587 84 payments
  9. FASENRA Respiratory $34,518 58 payments
  10. ProAir Digihaler $28,351 23 payments
  11. Other $192,562 744 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $12,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

885

Median for Allergy/ Immunology: 449

Drug cost

$2,130,828

Median for Allergy/ Immunology: $169,700

Branded share of claims

55%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orladeyo Berotralstat Hydrochloride Brand 15 $617,699
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 57 $396,626
Dupixent Pen Dupilumab Brand 35 $242,237
Panzyga Immun Glob G(Igg)-Ifas/Glycine Brand 18 $166,479
Xolair Omalizumab Brand 40 $116,713
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 13 $115,606
Nucala Mepolizumab Brand 31 $115,142
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $81,785
Dupixent Syringe Dupilumab Brand 21 $79,278
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 75 $60,391

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$479,384

Of which drugs: $429,501

Medicare patients

200

Average age 69

Services billed

30,461

143 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 56%
Depression 30%
COPD 27%
Osteoporosis 24%
Diabetes 21%
Ischemic heart disease 15%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
$86,105 31 —
AIRSUPRA
$36,811 — —
DUPIXENT
$32,048 56 —
TEZSPIRE
$28,853 13 —
Xhance
$15,640 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,823 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record